PPS.http://dx.doi.org/10.3346/jkms.2013.28.11.http://jkms.orgKim H, et
PPS.http://dx.doi.org/10.3346/jkms.2013.28.11.http://jkms.orgKim H, et al. ?Survival after Progression on GefitinibIn conclusion, resumed TKI use or pemetrexed use in NSCLC patients with acquired resistance to gefitinib is linked to longer PPS and…